Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 randomized clinical trial
JAMA Aug 17, 2021
Rovers KP, Bakkers C, Nienhuijs SW, et al. - Results of this phase 2 trial support the feasibility as well as safety of administering perioperative systemic therapy in patients diagnosed with resectable colorectal peritoneal metastases (CPM); this justifies a phase 3 trial.
An open-label, parallel-group phase 2 randomized clinical trial was performed in 9 Dutch tertiary centers.
The analysis was performed including 79 patients randomized to perioperative systemic therapy (experimental arm) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone (control arm).
No significant difference was there between the trial arms regarding the proportions of macroscopic complete cytoreductive surgery (experimental arm, 89%; control arm, 86%) and major postoperative morbidity (experimental arm, 22%; control arm, 33%).
Per findings, perioperative systemic therapy appeared feasible, safe, and able to induce response of CPM
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries